Inventor · disambiguated record
Xiaozhao Wang
Also filed as: Wang xiaozhao
46 granted patents·49 pending applications·335 citations·filing 2013–2025
98Inventor score
Top patents by PatentIndex Score
95 records- 0198US9758523B2Triazolopyridines and triazolopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Sep 12, 2017·21 cites·14 claims
- 0298US9695167B2Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·33 cites·41 claims
- 0397US11591338B2Pyrrolotriazine compounds as TAM inhibitorsINCYTE CORP·Filed 2020·Granted Feb 28, 2023·5 cites·4 claims
- 0497US10844069B2Pyrrolotriazine compounds as TAM inhibitorsINCYTE CORP·Filed 2019·Granted Nov 24, 2020·9 cites·19 claims
- 0597US10442810B2Pyrrolotriazine compounds as TAM inhibitorsINCYTE CORP·Filed 2018·Granted Oct 15, 2019·12 cites·25 claims
- 0697US10138249B2Triazolopyridines and triazolopyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Nov 27, 2018·15 cites·21 claims
- 0797US9981975B2Pyrrolotriazine compounds as tam inhibitorsINCYTE CORP·Filed 2017·Granted May 29, 2018·18 cites·4 claims
- 0897US9708318B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Jul 18, 2017·44 cites·41 claims
- 0997US9493442B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Nov 15, 2016·30 cites·47 claims
- 1096US10300051B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2016·Granted May 28, 2019·14 cites·35 claims
- 1195US11390624B2Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jul 19, 2022·4 cites·42 claims
- 1295US11247992B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2020·Granted Feb 15, 2022·3 cites·15 claims
- 1395US9695180B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2015·Granted Jul 4, 2017·24 cites·53 claims
- 1494US11673894B2Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitorsINCYTE CORP·Filed 2020·Granted Jun 13, 2023·4 cites·25 claims
- 1594US10968221B2Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2019·Granted Apr 6, 2021·6 cites·10 claims
- 1694US10174030B2Cyclopropylamines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Jan 8, 2019·14 cites·29 claims
- 1794US10125133B2Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Nov 13, 2018·15 cites·46 claims
- 1894US10112950B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2017·Granted Oct 30, 2018·15 cites·58 claims
- 1994US10053465B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2016·Granted Aug 21, 2018·16 cites·37 claims
- 2093US11976073B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2022·Granted May 7, 2024·2 cites·65 claims
- 2193US11530218B2Spiro compounds as inhibitors of KRASINCYTE CORP·Filed 2021·Granted Dec 20, 2022·3 cites·42 claims
- 2293US11136326B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2019·Granted Oct 5, 2021·6 cites·31 claims
- 2390US10556908B2Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitorsINCYTE CORP·Filed 2018·Granted Feb 11, 2020·8 cites·37 claims
- 2489US11161850B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Nov 2, 2021·5 cites·12 claims
- 2588US11168089B2Fused pyrimidine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Nov 9, 2021·5 cites·36 claims
- 2686US10519163B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2018·Granted Dec 31, 2019·4 cites·38 claims
- 2782US12415809B2Pyrrolotriazine compounds as tam inhibitorsINCYTE CORP·Filed 2023·Granted Sep 16, 2025·0 cites·33 claims
- 2880US11939328B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Mar 26, 2024·0 cites·35 claims
- 2980US2023357255A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2023·Application pending·0 cites
- 3079US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 3176US2025034153A1Triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 3276US2025041310A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 3375US12030884B2Pyrazoloquinoline KRAS inhibitorsINCYTE CORP·Filed 2022·Granted Jul 9, 2024·0 cites·26 claims
- 3475US11884665B2Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitorsINCYTE CORP·Filed 2022·Granted Jan 30, 2024·0 cites·12 claims
- 3575US2025313567A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 3675US2024360140A1Fused pyrazine derivatives as a2a / a2b inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 3775US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 3874US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 3973US2024400557A1Pyrazoloquinoline kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4073US2023124485A1Triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2022·Application pending·0 cites
- 4172US2024343742A1Vinyl imidazole compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 4270US2025206734A1Bicyclic heterocycles as mrgprx2 antagonistsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4369US2023192696A1Spiro compounds as inhibitors of krasINCYTE CORP·Filed 2022·Application pending·0 cites
- 4469US2025101020A1Spirocyclic lactam inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4569US2025188073A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 4668US2025179083A1Tricyclic triazolo compounds as dgk inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4768US2025333420A1Fused bicyclic pyrimidones as wrn inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4868US2025066363A1Bicyclic DGK InhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 4968US2025163079A1Kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 5067US11999740B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2021·Granted Jun 4, 2024·0 cites·36 claims
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Xiaozhao Wang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →